ReviewNature reviews. Microbiology2021
Pathogenesis of human cytomegalovirus in the immunocompromised host.
Review in Nature reviews. Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 391 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
391 citing papers in PubMed, 2 syntheses or guidelines pooled it, 596 citations in OpenAlex.
- Beyond valganciclovir: A meta-analysis of letermovir's safety and efficacy in cytomegalovirus prophylaxis after solid organ transplantation.BMC infectious diseases · 2026Pooled it
- Prevalence of respiratory viruses in children with respiratory tract infections during the COVID-19 pandemic era: a systematic review and meta-analysis.BMC pulmonary medicine · 2025Pooled it
- Prophylactic infusion of donor derived CMV specific T cells for the prevention of CMV reactivation following allogeneic HSCT.Scientific reports · 2025Trial
- Population Pharmacokinetics and Exposure-Response Relationships of Maribavir in Transplant Recipients With First Episode or Refractory Cytomegalovirus.CPT: pharmacometrics & systems pharmacology · 2025Trial
- Population pharmacokinetics and exposure-response relationships of maribavir in transplant recipients with cytomegalovirus infection.Journal of pharmacokinetics and pharmacodynamics · 2024Trial
- Clinical features and factors associated with severe illness in pediatric acute respiratory tract infections due to Escherichia coli: a retrospective tNGS-based study.World journal of microbiology & biotechnology · 2026Article
- New 1,3-Oxazole and 1,2,4-Oxadiazole Derivatives as Novel Agents Against Human Rhinovirus and Cytomegalovirus.ChemMedChem · 2026Article
- The human cytomegalovirus vGPCR UL33 is essential for efficient lytic replication in epithelial cells.Journal of virology · 2026Article
- UL45 of Human Cytomegalovirus Promotes Macrophage Survival and Modulates RIPK3-Associated Cell Death.Viruses · 2026Article
- Circular RNAs Associated with Human Cytomegalovirus Infection.Molecules (Basel, Switzerland) · 2026Review
- Topical versus oral antiviral therapy for cytomegalovirus anterior uveitis: a multicenter study in Taiwan.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Human Cytomegalovirus Genetic Diversity, Clinical Relevance, and Emerging Insights.Reviews in medical virology · 2026Review
- Fibrin-rich environment drives catheter-associated UTIs by suppressing macrophage defenses.Nature communications · 2026Article
- Detection of Human CytomegalovirusThe journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2026Article
- The human cytomegalovirus chemokine binding protein UL22A is necessary for efficient reactivation from latency in CD34Journal of virology · 2026Article
- A comparative performance evaluation of the VIDAS cytomegalovirus (CMV) interferon-gamma release assay (IGRA) and T-SPOT CMV for measuring CMV-specific T-cell responses in allogeneic hematopoietic stem cell transplant recipients receiving letermovir prophylaxis.Journal of clinical microbiology · 2026Article
- LB-PaCS-MD Guided Simulations Reveal Transient Stabilization during TCR-pMHC Dissociation.Journal of chemical information and modeling · 2026Article
- Development of ganciclovir as an anti-human cytomegalovirus drug: historical perspectives and future prospects.The Journal of general virology · 2026Review
- Glutamine supports human cytomegalovirus induced lipidome remodeling through reductive carboxylation.PLoS pathogens · 2026Article
- Renaissance of antiviral CD8Nature reviews. Immunology · 2026Review
331 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Human cytomegalovirus (HCMV) is a herpesvirus that infects ~60% of adults in developed countries and more than 90% in developing countries. Usually, it is controlled by a vigorous immune response so that infections are asymptomatic or symptoms are mild. However, if the immune system is compromised, HCMV can replicate to high levels and cause serious end organ disease. Substantial progress is being made in understanding the natural history and pathogenesis of HCMV infection and disease in the immunocompromised host. Serial measures of viral load defined the dynamics of HCMV replication and are now used routinely to allow intervention with antiviral drugs in individual patients. They are also used as pharmacodynamic read-outs to evaluate prototype vaccines that may protect against HCMV replication and to define immune correlates of this protection. This novel information is informing the design of randomized controlled trials of new antiviral drugs and vaccines currently under evaluation. In this Review, we discuss immune responses to HCMV and countermeasures deployed by the virus, the establishment of latency and reactivation from it, exogenous reinfection with additional strains, pathogenesis, development of end organ disease, indirect effects of infection, immune correlates of control of replication, current treatment strategies and the evaluation of novel vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.